CDK
CDK (Cyclin-Dependent Kinase) inhibitors are compounds that block the activity of CDKs, a group of protein kinases that regulate the cell cycle, transcription, and other cellular processes. CDKs are activated by binding to cyclins, and their activity is crucial for the progression of cells through different phases of the cell cycle. Inhibiting CDKs can halt cell division, leading to cell cycle arrest and apoptosis, particularly in cancer cells where CDKs are often dysregulated. CDK inhibitors are widely used in cancer research and have therapeutic potential in treating various cancers. At CymitQuimica, we provide a comprehensive selection of high-quality CDK inhibitors to support your research in cell cycle control, cancer, and therapeutic development.
Found 500 products of "CDK"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
CDK7-IN-2 hydrochloride hydrate
CAS:<p>CDK7-IN-2 HCl hydrate is a potent, specific CDK7 enzyme inhibitor with significant anti-cancer effects.</p>Formula:C26H42ClN7O4Color and Shape:SolidMolecular weight:552.123-Methylthienyl-carbonyl-JNJ-7706621
CAS:<p>Potent CDK inhibitor 3-Methylthienyl-carbonyl-JNJ-7706621, IC50: CDK1=6.4nM, CDK2=2nM, GSK-3=0.041μM; moderate on CDK4/VEGF-R2/FGF-R2.</p>Formula:C14H14N6O3S2Color and Shape:SolidMolecular weight:378.43LSN3106729 hydrochloride
CAS:<p>LSN3106729 hydrochloride, an Abemaciclib metabolite, is a CDK-inhibiting antitumor PROTAC CDK4/6 degrader.</p>Formula:C25H29ClF2N8OColor and Shape:SoildMolecular weight:531.00Olomoucine
CAS:<p>Olomoucine hinders Cdk2, Cdc2, CDK5, ERK1, regulates the cell cycle, and fights melanoma; IC50s: 3-25 µM.</p>Formula:C15H18N6OPurity:99.77%Color and Shape:White Crystalline PowderMolecular weight:298.34PP-C8
<p>PP-C8: PROTAC CDK12-Cyclin K degrader with DC50s 416/412 nM; synergizes with PARP inhibitor against TNBC.</p>Formula:C43H51FN12O7Color and Shape:SolidMolecular weight:866.94PROTAC CDK9 degrader-7
CAS:<p>PROTAC CDK9 degrader-7 is a proteolysis-targeting chimera (PROTAC) specifically designed to target and mediate the degradation of Cyclin-Dependent Kinase 9 (</p>Formula:C43H50Cl2N8O9Color and Shape:SoildMolecular weight:893.81BSJ-03-204
CAS:<p>BSJ-03-204 is a selective Cdk4/6 degrader.</p>Formula:C43H48N10O8Color and Shape:SolidMolecular weight:832.9CGP-74514
CAS:<p>CGP-74514,CDK1 inhibitor (IC50=25 nM). Induces G2/M arrest, apoptosis. Used in bladder cancer research.</p>Formula:C19H24ClN7Purity:98.54%Color and Shape:SoildMolecular weight:385.89PROTAC CDK9 degrader 4
CAS:<p>PROTAC CDK9 degrader 4 is a CDK9 degrader that targets transcriptional regulation and has potential anticancer activity.</p>Formula:C43H56N10O5Color and Shape:SolidMolecular weight:792.97JH-XVI-178
CAS:<p>JH-XVI-178: potent CDK8/19 inhibitor with good pharmacokinetics, low clearance, moderate oral bioavailability.</p>Formula:C22H22ClN7OColor and Shape:SolidMolecular weight:435.92FDA-Approved Kinase Inhibitor Library
<p>A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.</p>Color and Shape:LiquidKinase Inhibitor Library
<p>A unique collection of 2720 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;</p>Color and Shape:Odour SolidCDK7-IN-6
CAS:<p>CDK7-IN-6, a potent CDK7 inhibitor (IC50 ≤100 nM), from WO2019197549 A1, is >200x selective over CDK1/2/5, promising for cancer research.</p>Formula:C26H34ClN9OColor and Shape:SolidMolecular weight:524.07PROTAC CDK9 degrader-5
CAS:<p>PROTAC CDK9 degrader-5 selectively degrades CDK9 isoforms 42, 55 with DC50 of 0.10μM, 0.14μM via proteasome.</p>Formula:C42H48Cl2N8O9Purity:98%Color and Shape:SolidMolecular weight:879.78AM5992
CAS:<p>AM5992 (example 195) is a potent CDK4 and CDK6 inhibitor (CDK4, IC50= 0.013 μM). AM5992 can be used for the research of CDK4-mediated disorders.</p>Formula:C27H33FN8OPurity:98%Color and Shape:SoildMolecular weight:504.6HTH-01-091 TFA
<p>HTH-01-091 TFA: Potent, selective MELK inhibitor (IC50=10.5 nM); also targets PIM1/2/3, RIPK2, DYRK3, smMLCK, CLK2; used in breast cancer research.</p>Formula:C28H29Cl2F3N4O4Color and Shape:SolidMolecular weight:613.46CDK-IN-12
CAS:<p>CDK-IN-12 (Example 20), a CDK inhibitor, effectively inhibits CDK4/6, demonstrating IC50 values below 20 nM [1].</p>Formula:C26H29FN6OSColor and Shape:SolidMolecular weight:492.61CDK12-IN-4
CAS:<p>CDK12-IN-4 is a pyrazolotriazine that inhibits CDK12 (IC50: 0.641 μM) with high ATP (2 mM) and spares CDK2/Cyclin E and CDK9/Cyclin T1 (IC50: >20 μM).</p>Formula:C20H20F2N8OColor and Shape:SolidMolecular weight:426.432SNX7
CAS:<p>SNX7 (WAY-323879) inhibits CDKI pathway; useful for studying aging and related diseases.</p>Formula:C15H14N2OPurity:99.05%Color and Shape:SolidMolecular weight:238.28CDK6/9-IN-1
CAS:<p>CDK6/9-IN-1, an oral dual inhibitor of CDK6/9, has IC50s of 40.5nM (CDK6) and 39.5nM (CDK9).</p>Formula:C22H25ClN8OColor and Shape:SolidMolecular weight:452.95LL-K8-22
<p>LL-K8-22: potent CDK8/cyclin C degrader; DC50 ~2.5μM; hinders STAT1 phosphorylation; curbs E2F/MYC cancer pathways; for TNBC study.</p>Formula:C37H43N5OColor and Shape:SolidMolecular weight:573.77CDK4/6-IN-11
CAS:<p>CDK4/6-IN-11 is a potent PROTAC CDK4/6 degrader.</p>Formula:C43H49N11O7Color and Shape:SolidMolecular weight:831.92PROTAC FLT3/CDKs degrader-1
<p>PROTACFLT3/CDKs degrader-1 (Compound C3) is an agent that degrades cyclin-dependent kinase (CDK2 with a DC50 of 18.73 nM) and FMS-like tyrosine kinase 3 (FLT3). It induces differentiation in HL-60 cells, achieving a 72.77% differentiation rate at 6.25 nM, and inhibits proliferation of acute myeloid leukemia (AML) cells, with an IC50 ranging from 2.9 to 37 nM. PROTACFLT3/CDKs degrader-1 demonstrates potential for improving the treatment of AML.</p>Formula:C40H42N12O5Molecular weight:770.34011Men 10376
CAS:<p>Men 10376 is a selective antagonist of tachykinin NK-2 receptor. It has a Ki of 4.4 μM for rat small intestine NK-2 receptor.</p>Formula:C57H68N12O10Purity:98%Color and Shape:SolidMolecular weight:1081.22CDK7-IN-5
CAS:<p>CDK7-IN-5, a CDK7 inhibitor with an IC 50 value of less than 100 nM, exhibits potent anticancer properties (WO2015154022A1, Compound 104).</p>Formula:C34H45N9O2Color and Shape:SolidMolecular weight:611.795PROTAC CDK9 degrader-2
CAS:<p>PROTAC CDK9 degrader-2, potent, selective, IC50 17 μM in MCF-7, wogonin-derived, targets CRBN.</p>Formula:C39H36N6O10Purity:98%Color and Shape:SolidMolecular weight:748.74XY028-133
CAS:<p>XY028-133 is a PROTAC-based CDK4/6 degrader for the study of tumors.</p>Formula:C53H67N11O7SPurity:97.11%Color and Shape:SolidMolecular weight:1002.23Cdk2/Cyclin Inhibitory Peptide II
CAS:<p>Cdk2/Cyclin Inhibitory Peptide II (Tat-LDL), a CDK2 inhibitor, demonstrates dose-dependent cytotoxic effects on U2OS osteosarcoma cells [1].</p>Formula:C110H200N48O25Color and Shape:SolidMolecular weight:2595.07EGFR/CDK2-IN-4
<p>EGFR/CDK2-IN-4 (compound 4c) is a dual inhibitor targeting EGFR and CDK-2, demonstrating IC50 values of 89.6 nM for EGFR and 165.4 nM for CDK-2.</p>Formula:C24H16N6OS2Purity:98%Color and Shape:SolidMolecular weight:468.55BSJ-04-132
<p>Selective Cdk4 degrader. Degrades Cdk4 in Molt-4 cells, with no effect on Cdk6 levels. Displays cereblon-dependent degradation.</p>Color and Shape:LiquidCDK4/6-IN-5
CAS:<p>CDK4/6-IN-5 inhibits CDK4/6; Ki: 0.2 nM (CDK4/D1) & 4.4 nM (CDK6/D3). (WO2019207463A1, A93)</p>Formula:C22H28ClFN6O4SColor and Shape:SolidMolecular weight:527.01Multi-target kinase inhibitor 2
<p>Compound 5K (Multi-target kinase inhibitor 2) is a multi-targeted kinase inhibitor demonstrating activity against EGFR, Her2, VEGFR2, and CDK2 with IC50 values</p>Purity:98%Color and Shape:Odour SolidCDK12-IN-6
CAS:<p>CDK12-IN-6, a pyrazolotriazine, strongly inhibits CDK12 (IC50 1.19 μM at 2 mM ATP), but not CDK2/Cyclin E or CDK9/Cyclin T1 (both IC50 >20 μM).</p>Formula:C20H21F2N9Color and Shape:SolidMolecular weight:425.448TMX-2138
CAS:<p>TMX-2138 is a CDKs PROTAC degrader, with IC50 values of 8.7 nM for CDK1/cyclinB, 10.9 nM for CDK2/cyclinA, 7.0 nM for CDK5/p25, and 25.7 nM for CDK9/cyclinT1. It enhances the ubiquitination and degradation of CDKs and is utilized for ovarian cancer research.</p>Formula:C40H43BrFN9O11SColor and Shape:SolidMolecular weight:956.791CDK9 inhibitor HH1
CAS:<p>CDK9 inhibitor HH1 (8019-9719) is an inhibitor of the human CDK2-cyclin A2 complex with an IC50 value of 2 μM.</p>Formula:C13H15N3OSPurity:99.92%Color and Shape:SolidMolecular weight:261.34Abemaciclib metabolite M18
CAS:<p>Abemaciclib M18 (LSN3106729), a potent CDK inhibitor with antitumor action, used in a PROTAC to degrade CDK4/6.</p>Formula:C25H28F2N8OPurity:98%Color and Shape:SolidMolecular weight:494.54PROTAC CDK9 degrader-8
<p>PROTAC CDK9 Degrader-8 (Compound 21) is a potent degrader of CDK9 with an IC50 of 0.01 μM, utilized in cancer research [1].</p>Formula:C44H52Cl2N10O7Purity:98%Color and Shape:SolidMolecular weight:903.85CDK9-IN-25
<p>CDK9-IN-25 (compound 4a), an imidazopyrazine derivative, functions as a CDK9 inhibitor with an IC50 of 0.24 μM.</p>Formula:C15H16FN5Purity:98%Color and Shape:SolidMolecular weight:285.32EGFR/CDK2-IN-2
<p>EGFR/CDK2-IN-2 (compound 6a) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 19.6 nM and 87.9 nM, respectively.</p>Formula:C49H32N12O2S2Purity:98%Color and Shape:SolidMolecular weight:884.99Cdk2/Cyclin Inhibitory Peptide I
<p>CDK2, a Ser/Thr kinase, is akin to yeast cdc28 and human Cdk1, crucial for cell division.</p>Formula:C111H196N48O23Purity:98%Color and Shape:SolidMolecular weight:2571.05CDK7-IN-7
CAS:<p>CDK7-IN-7: Selective CDK7 inhibitor, IC50 < 50 nM (Patent CN112661745A).</p>Formula:C20H20BrF3N6O2Color and Shape:SolidMolecular weight:513.319[pThr3]-CDK5 Substrate
CAS:<p>[pThr3]-CDK5 Substrate is an effective Phospho-Thr3CDK5 Substrate.[pThr3]-CDK5 Substrate is phosphorylated by CDK5 with a Km value of 6 µM[1].</p>Formula:C53H100N15O15PPurity:98%Color and Shape:SolidMolecular weight:1218.43PROTAC CDK9 degrader-11
CAS:<p>PROTAC CDK9 degrader-11 (Compound C3) is an orally active PROTAC CDK9 degrader with a DC50 of 1.09 nM. This compound exhibits cytotoxicity in small cell lung cancer (SCLC) cells, with IC50 values in the nanomolar range. It induces cell cycle arrest at the G0/G1 phase and inhibits cell invasion in DMS114 and DMS53 cells. In addition, PROTAC CDK9 degrader-11 shows antitumor activity in an NCI-H446 xenograft mouse model. (Pink: ligand for target protein CDK9 ligand 3; Black: linker; Blue: ligand for E3 ligase Cereblon E3 ligase Ligand 56)</p>Formula:C39H48Cl2N10O5Color and Shape:SolidMolecular weight:807.768IV-361
CAS:<p>IV-361, an orally active and selective CDK7 inhibitor with a Ki value of less than or equal to 50 nM, demonstrates potent anti-cancer activity (US20190256531A1</p>Formula:C23H32FN5O2SiColor and Shape:SolidMolecular weight:457.625EGFR/CDK2-IN-3
<p>EGFR/CDK2-IN-3 (compound 4b) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 71.7 nM and 113.7 nM, respectively.</p>Formula:C30H20N6OSPurity:98%Color and Shape:SolidMolecular weight:512.58CDK5-IN-1
CAS:<p>CDK5-IN-1: Potent CDK5 inhibitor (<10 nM) used in kidney disease research.</p>Formula:C24H25FN6O3SColor and Shape:SolidMolecular weight:496.56YKL-5-124 TFA
CAS:<p>YKL-5-124 TFA is a potent CDK7 inhibitor (IC50: 53.5 nM), more than 100x selective over CDK9/2, not active on CDK12/13, and disrupts the cell cycle.</p>Formula:C30H34F3N7O5Color and Shape:SolidMolecular weight:629.63Cell Cycle Compound Library
<p>A unique collection of xnum cell cycle related compounds for high throughput screening (HTS) and high content screening (HCS);</p>Color and Shape:Odour SolidCDK2-IN-43
<p>CDK2-IN-43 (Compound 3a) is a CDK2-cyclin E2 inhibitor with an IC50 value of 6.0 nM. It is applicable to cancer research.</p>Formula:C19H27N7OColor and Shape:SolidMolecular weight:369.464CDK1-IN-2
CAS:<p>CDK1-IN-2 (cdk1 inhibitor 2) is a CDK1 inhibitor with IC50 of 5.8 μM.</p>Formula:C17H11ClN2OPurity:98.53%Color and Shape:SoildMolecular weight:294.73
![[pThr3]-CDK5 Substrate](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FTM%2Fthumb-webp%2FTP1602.webp&w=3840&q=75)
